August 09, 2021
1 min read
Save
FDA grants orphan drug designation to ADX-2191 for retinitis pigmentosa
The FDA has granted orphan drug designation to ADX-2191 for the treatment of retinitis pigmentosa, according to a press release from Aldeyra Therapeutics.
Currently, there are no approved drug treatments for retinitis pigmentosa.
“ADX-2191 has now received orphan designations for three distinct clinical indications, highlighting the broad platform potential of ADX-2191 to treat an array of rare retinal disorders,” Todd C. Brady, MD, PhD, president and CEO of Aldeyra, said in the release.
ADX-2191 (methotrexate for intravitreal injection) previously received the designation to treat primary vitreoretinal lymphoma and to prevent proliferative vitreoretinopathy.
Published by:
Read more about